Oncology Clinical Trials in New York, NY

As of July 2026, 803 paid clinical trials are recruiting for Oncology in New York, New York. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

809 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

Sites in New York, The Bronx +56 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

Drug: Zongertinib

Sites in New York, Shirley +24 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

Drug: Intismeran autogene

Sites in New York, The Bronx +46 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

Sites in New York, The Bronx +26 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

Sites in New York, Lake Success +22 more locations

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

Sites in New York, Uniondale +56 more locations

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Daratumumab

Sites in New York, Mineola +64 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

Sites in New York, Williamsville +47 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

Sites in New York, Mineola +30 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

Sites in New York +24 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

Sites in New York, Rochester +40 more locations

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

Sites in New York, Mineola +46 more locations

Sponsor: Celgene

Sex: Male·Age: 18+

Code: NCT06764485·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

for Ovarian Cancer

Drug: Bevacizumab

Sites in New York +31 more locations

Sponsor: Daiichi Sankyo

Sex: Female·Age: 18+

Code: NCT06819007·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

for Melanoma

Sites in New York +30 more locations

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05355701·Phase 1·Recruiting·Listed May 2022

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

Sites in New York +23 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

Sites in New York +25 more locations

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

for Urothelial Carcinoma

Sites in New York, Long Island City +142 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04879329·Phase 2·Recruiting·Listed May 2021

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

Sites in New York +30 more locations

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

for Cervical Cancer

Sites in New York, Brooklyn +90 more locations

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT06952660·Phase 4·Recruiting·Listed May 2025

Apply to this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for Metastatic Breast Cancer

Sites in New York +30 more locations

Sponsor: LeonaBio

Sex: All·Age: 18+

Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

Sites in New York, The Bronx +21 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for Head and Neck Squamous Cell Carcinoma

Sites in New York +28 more locations

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT06163534·Recruiting·Listed Dec 2023

Apply to this trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostate Cancer

Sites in New York +22 more locations

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT04221542·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

for Non-small Cell Lung Cancer

Drug: Relatlimab

Sites in New York, Syracuse +36 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06561386·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

for B-cell Malignancy

Sites in New York, Buffalo +26 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05006716·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

Sites in New York, The Bronx +30 more locations

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Sites in New York +22 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

Sites in New York +28 more locations

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

for Prostate Cancer

Sites in New York, The Bronx +23 more locations

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT06855277·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for Cancer

Sites in New York +29 more locations

Sponsor: Parabilis Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

Sites in New York, Syracuse +74 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for Breast Cancer

Sites in New York, Stony Brook +47 more locations

Sponsor: Greenwich LifeSciences, Inc.

Sex: All·Age: 18 - 100

Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

for Multiple Myeloma

Drug: Elranatamab

Sites in New York, Long Island City +32 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06215118·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in New York, Buffalo +36 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

Sites in New York, The Bronx +28 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for Prostate Cancer

Sites in New York +26 more locations

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male·Age: 18+

Code: NCT06056830·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

for Glioblastoma

Sites in New York, The Bronx +30 more locations

Sponsor: NovoCure GmbH

Sex: All·Age: 18+

Code: NCT06556563·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

for Breast Cancer

Sites in New York, The Bronx +77 more locations

Sponsor: BriaCell Therapeutics Corporation

Sex: All·Age: 18+

Code: NCT06072612·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

for Chronic Lymphocytic Leukemia

Drug: Venetoclax

Sites in New York +30 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06428019·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

Sites in New York, The Bronx +28 more locations

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

Conditions in Oncology (New York, NY)

Solid tumor· 130 Non-small cell lung cancer (NSCLC)· 102 Breast cancer· 99 Prostate cancer· 72 Cancer (any)· 62 Colorectal cancer· 53 Pancreatic cancer· 53 Multiple myeloma· 48 Ovarian cancer· 44 Non-Hodgkin lymphoma· 39 Acute myeloid leukemia (AML)· 37 Endometrial cancer· 36 Head and neck cancer· 30 Lung cancer· 28 Metastatic breast cancer· 26 Bladder cancer· 25 Gastric cancer· 22 Esophageal cancer· 22 Melanoma· 21 Glioblastoma· 20 Glioma· 18 Leukemia (other)· 18 Hematologic malignancy· 17 Metastatic prostate cancer· 16 Kidney cancer· 16 Chronic lymphocytic leukemia (CLL)· 16 Myelodysplastic syndromes (MDS)· 16 Diffuse large B-cell lymphoma (DLBCL)· 15 Triple-negative breast cancer· 13 Cervical cancer· 13 Brain cancer· 13 Myelofibrosis· 12 Sarcoma· 12 Biliary tract cancer· 11 Acute lymphoblastic leukemia· 10 Follicular lymphoma· 10 Thyroid cancer· 10 Mesothelioma· 10 Rectal cancer· 9 Neuroblastoma· 9 HER2-negative breast cancer· 8 Liver cancer· 8 Fallopian tube cancer· 8 Hodgkin lymphoma· 8 HER2-positive breast cancer· 7 Gastroesophageal junction cancer· 7 Small lymphocytic lymphoma· 7 Small cell lung cancer· 6 Colon cancer· 6 Mantle cell lymphoma· 6 Ewing sarcoma· 6 Brain metastases· 5 Osteosarcoma· 5 Gastrointestinal cancer· 4 Gynecologic cancer· 4 Marginal zone lymphoma· 4 Skin cancer· 4 Soft tissue sarcoma· 4 Metastatic colorectal cancer· 3 Neuroendocrine tumors· 3 Uterine cancer· 2 Chronic myelomonocytic leukemia· 2 Myeloproliferative neoplasm· 2 Burkitt lymphoma· 2 Pediatric cancer· 2